This reengineered HPV vaccine trains T cells to hunt down cancer
Science Daily
February 18, 2026
Northwestern researchers have shown that when it comes to cancer vaccines, arrangement can be just as important as ingredients. By repositioning a small fragment of an HPV protein on a DNA-based nanovaccine, the team dramatically strengthened the immune system’s attack on HPV-driven tumors. One specific design slowed tumor growth, extended survival in animal models, and unleashed far more cancer-killing T cells than other versions made with the exact same components.
Verticals
scienceresearch
Originally published on Science Daily on 2/18/2026